STANDARD_NAME	GSE9006_HEALTHY_VS_TYPE_1_DIABETES_PBMC_1MONTH_POST_DX_UP
SYSTEMATIC_NAME	M5777
COLLECTION	C7:IMMUNESIGDB
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GSE9006_HEALTHY_VS_TYPE_1_DIABETES_PBMC_1MONTH_POST_DX_UP
NAMESPACE	HUMAN_GENE_SYMBOL
DESCRIPTION_BRIEF	Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from healthy donors versus PBMCs from patients with type 1 diabetes at 1 month after the diagnosis.
DESCRIPTION_FULL	Objective: We hypothesized that type 1 diabetes (T1D) is accompanied by changes in gene expression in peripheral blood mononuclear cells (PBMCs) due to dysregulation of adaptive and innate immunity, counterregulatory responses to immune dysregulation, insulin deficiency and hyperglycemia. Research Design and Methods: Microarray analysis was performed on PBMCs from 43 patients with newly diagnosed T1D, 12 patients with newly diagnosed type 2 diabetes (T2D) and 24 healthy controls. One and four month follow-up samples were obtained from 20 of the T1D patients. Results: Microarray analysis identified 282 genes differing in expression between newlydiagnosed T1D patients and controls at a false discovery rate of 0.05. Changes in expression of interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2) resolved within four months of insulin therapy and were also observed in T2D suggesting that they resulted from hyperglycemia. With use of a knowledge base, 81/282 genes could be placed within a network of interrelated genes with predicted functions including apoptosis and cell proliferation. IL1B and the MYC oncogene were the most highly-connected genes in the network. IL1B was highly overexpressed in both T1D and T2D, whereas MYC was dysregulated only in T1D. Conclusion: T1D and T2D likely share a final common pathway for beta cell dysfunction that includes secretion of interleukin-1β and prostaglandins by immune effector cells, exacerbating existing beta cell dysfunction, and causing further hyperglycemia. The results identify several targets for disease-modifying therapy of diabetes and potential biomarkers for monitoring treatment efficacy.
PMID	17595242
GEOID	GSE9006
AUTHORS	Kaizer EC,Glaser CL,Chaussabel D,Banchereau J,Pascual V,White PC
CONTRIBUTOR	Jernej Godec
CONTRIBUTOR_ORG	Dana-Farber Cancer Institute
EXACT_SOURCE	GSE9006_2238_200_UP
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	
SOURCE_MEMBERS	AAMP,AATF,ACO2,ACTG1,ACTR2,ADAM10,ADNP2,AGPS,AHCY,ALDOA,ANP32A,ANXA5,ARL6IP1,ARPC4,ASCL2,ATMIN,ATP5B,AZIN1,BAG1,BCAP31,BLK,BMPR2,BNIP2,BTBD1,C11orf57,C17orf85,C19orf2,C7orf42,C8orf33,CANX,CD69,CHEK2,CLN8,CLP1,COPA,COPS7B,CORO1C,CPNE3,CPSF6,CSDA,CSDE1,CSNK1G3,CXCL5,CYBB,DAZAP2,DDIT4,DDX3X,DDX49,DNAJA2,DNAJB14,DPYSL2,DR1,DUSP10,DUSP5,ECSIT,EIF1AX,EIF3I,EIF4G3,ENSA,EZR,FAM13A,FAM46C,FARSA,FLI1,FOXK2,G3BP2,GALNT1,GALNT12,GDI2,GLUD1,GLUD2,GPAA1,GPI,GSR,HADHA,HIF1A,HIST3H3,HMGB1,HNRNPA1,HNRNPA3,HNRNPD,HNRNPH2,HNRNPM,HNRNPR,HNRNPU,HSP90B1,HSPA5,HSPA9,IDS,IER5,ILVBL,INPP5D,ITGB3,JUN,JUNB,KCTD3,KDELR2,KLF10,KPNA5,KPNB1,LAPTM5,LRIG2,LSM12,LSM14A,LYPLA1,MAP2K1,MAPK1IP1L,MAPRE1,MATR3,MBD2,MDM4,MKRN1,MRPL12,MRPS10,MSN,MTHFD1,NADSYN1,NAPG,NDUFV1,NNT,NPTN,NRAS,NUS1P3,ODF2,ORAI2,OSTF1,PABPC4,PAK2,PCBP2,PCNP,PDIA3,PDIA4,PDZK1IP1,PIK3R1,PKN1,POTEKP,PPP1CB,PPP3CB,PRIM2,PRKAA1,PRKDC,PSMC3,PSMD2,PSPN,PTP4A2,QARS,QKI,RAB40B,RBBP4,RBM3,RBM39,RNF11,RNF38,RNPS1,ROD1,RPN1,RTN3,SAFB,SAFB2,SART1,SEC31A,SFN,SFPQ,SIDT1,SIK1,SLC35A2,SLC35A3,SLC39A7,SMARCA2,SNTB2,SNX6,SOX4,SPCS3,SRRT,SRSF9,STAU1,STK17B,STT3A,STX8,SUMO3,SYNE2,TAP2,TMED2,TMEM9B,TMOD3,TOB1,TOMM22,TPST2,TRAM1,TRIM16,TXNIP,UGCG,UQCRC1,WDR18,WTAP,XAB2,XRCC6,YWHAZ,ZNF394,ZNF551
GENE_SYMBOLS	AAMP,AATF,ACO2,ACTG1,ACTR2,ADAM10,ADNP2,AGPS,AHCY,ALDOA,ANP32A,ANXA5,ARL6IP1,ARPC4,ASCL2,ATMIN,ATP5F1B,AZIN1,BAG1,BCAP31,BLK,BMPR2,BNIP2,BTBD1,NKAPD1,NCBP3,URI1,TMEM248,C8orf33,CANX,CD69,CHEK2,CLN8,CLP1,COPA,COPS7B,CORO1C,CPNE3,CPSF6,YBX3,CSDE1,CSNK1G3,CXCL5,CYBB,DAZAP2,DDIT4,DDX3X,DDX49,DNAJA2,DNAJB14,DPYSL2,DR1,DUSP10,DUSP5,ECSIT,EIF1AX,EIF3I,EIF4G3,ENSA,EZR,FAM13A,TENT5C,FARSA,FLI1,FOXK2,G3BP2,GALNT1,GALNT12,GDI2,GLUD1,GLUD2,GPAA1,GPI,GSR,HADHA,HIF1A,H3-4,HMGB1,HNRNPA1,HNRNPA3,HNRNPD,HNRNPH2,HNRNPM,HNRNPR,HNRNPU,HSP90B1,HSPA5,HSPA9,IDS,IER5,ILVBL,INPP5D,ITGB3,JUN,JUNB,KCTD3,KDELR2,KLF10,KPNA5,KPNB1,LAPTM5,LRIG2,LSM12,LSM14A,LYPLA1,MAP2K1,MAPK1IP1L,MAPRE1,MATR3,MBD2,MDM4,MKRN1,MRPL12,MRPS10,MSN,MTHFD1,NADSYN1,NAPG,NDUFV1,NNT,NPTN,NRAS,NUS1P3,ODF2,ORAI2,OSTF1,PABPC4,PAK2,PCBP2,PCNP,PDIA3,PDIA4,PDZK1IP1,PIK3R1,PKN1,POTEKP,PPP1CB,PPP3CB,PRIM2,PRKAA1,PRKDC,PSMC3,PSMD2,PSPN,PTP4A2,EPRS1,QKI,RAB40B,RBBP4,RBM3,RBM39,RNF11,RNF38,RNPS1,PTBP3,RPN1,RTN3,SAFB,SAFB2,SART1,SEC31A,SFN,SFPQ,SIDT1,SIK1,SLC35A2,SLC35A3,SLC39A7,SMARCA2,SNTB2,SNX6,SOX4,SPCS3,SRRT,SRSF9,STAU1,STK17B,STT3A,STX8,SUMO3,SYNE2,TAP2,TMED2,TMEM9B,TMOD3,TOB1,TOMM22,TPST2,TRAM1,TRIM16,TXNIP,UGCG,UQCRC1,WDR18,WTAP,XAB2,XRCC6,YWHAZ,ZNF394,ZNF551
FOUNDER_NAMES